These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 18468487)

  • 1. Front-runners for pharmacotherapeutic correction of the airway ion transport defect in cystic fibrosis.
    Clunes MT; Boucher RC
    Curr Opin Pharmacol; 2008 Jun; 8(3):292-9. PubMed ID: 18468487
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The epithelium as a target for therapy in cystic fibrosis.
    Thelin WR; Boucher RC
    Curr Opin Pharmacol; 2007 Jun; 7(3):290-5. PubMed ID: 17475561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cystic fibrosis lung disease starts in the small airways: can we treat it more effectively?
    Tiddens HA; Donaldson SH; Rosenfeld M; Paré PD
    Pediatr Pulmonol; 2010 Feb; 45(2):107-17. PubMed ID: 20082341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacotherapy of the ion transport defect in cystic fibrosis: role of purinergic receptor agonists and other potential therapeutics.
    Kunzelmann K; Mall M
    Am J Respir Med; 2003; 2(4):299-309. PubMed ID: 14719996
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New pulmonary therapies directed at targets other than CFTR.
    Donaldson SH; Galietta L
    Cold Spring Harb Perspect Med; 2013 Jun; 3(6):. PubMed ID: 23732851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacologic modulation of salt and water in the airway epithelium in cystic fibrosis.
    Knowles MR; Olivier K; Noone P; Boucher RC
    Am J Respir Crit Care Med; 1995 Mar; 151(3 Pt 2):S65-9. PubMed ID: 7533608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New generation ENaC inhibitors detach cystic fibrosis airway mucus bundles via sodium/hydrogen exchanger inhibition.
    Giorgetti M; Klymiuk N; Bähr A; Hemmerling M; Jinton L; Tarran R; Malmgren A; Åstrand A; Hansson GC; Ermund A
    Eur J Pharmacol; 2021 Aug; 904():174123. PubMed ID: 33974881
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Denufosol tetrasodium in patients with cystic fibrosis and normal to mildly impaired lung function.
    Accurso FJ; Moss RB; Wilmott RW; Anbar RD; Schaberg AE; Durham TA; Ramsey BW;
    Am J Respir Crit Care Med; 2011 Mar; 183(5):627-34. PubMed ID: 21169471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Update in cystic fibrosis 2008.
    Ratjen F
    Am J Respir Crit Care Med; 2009 Mar; 179(6):445-8. PubMed ID: 19264980
    [No Abstract]   [Full Text] [Related]  

  • 10. Inhaled P2Y2 receptor agonists as a treatment for patients with Cystic Fibrosis lung disease.
    Kellerman D; Evans R; Mathews D; Shaffer C
    Adv Drug Deliv Rev; 2002 Dec; 54(11):1463-74. PubMed ID: 12458155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological approaches to correcting the ion transport defect in cystic fibrosis.
    Roomans GM
    Am J Respir Med; 2003; 2(5):413-31. PubMed ID: 14719993
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of Protease-Epithelial Sodium Channel Signaling Improves Mucociliary Function in Cystic Fibrosis Airways.
    Reihill JA; Walker B; Hamilton RA; Ferguson TE; Elborn JS; Stutts MJ; Harvey BJ; Saint-Criq V; Hendrick SM; Martin SL
    Am J Respir Crit Care Med; 2016 Sep; 194(6):701-10. PubMed ID: 27014936
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rationale for hypertonic saline therapy for cystic fibrosis lung disease.
    Tarran R; Donaldson S; Boucher RC
    Semin Respir Crit Care Med; 2007 Jun; 28(3):295-302. PubMed ID: 17562499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic options for hydrating airway mucus in cystic fibrosis.
    Tildy BE; Rogers DF
    Pharmacology; 2015; 95(3-4):117-32. PubMed ID: 25823699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Small Molecule Anion Carriers Correct Abnormal Airway Surface Liquid Properties in Cystic Fibrosis Airway Epithelia.
    Gianotti A; Capurro V; Delpiano L; Mielczarek M; García-Valverde M; Carreira-Barral I; Ludovico A; Fiore M; Baroni D; Moran O; Quesada R; Caci E
    Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32098269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Osmolytes and ion transport modulators: new strategies for airway surface rehydration.
    Goralski JL; Boucher RC; Button B
    Curr Opin Pharmacol; 2010 Jun; 10(3):294-9. PubMed ID: 20439165
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ion channels as targets to treat cystic fibrosis lung disease.
    Martin SL; Saint-Criq V; Hwang TC; Csanády L
    J Cyst Fibros; 2018 Mar; 17(2S):S22-S27. PubMed ID: 29102290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The epithelial sodium channel (ENaC) as a therapeutic target for cystic fibrosis lung disease.
    Moore PJ; Tarran R
    Expert Opin Ther Targets; 2018 Aug; 22(8):687-701. PubMed ID: 30028216
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 17beta-Estradiol inhibits Ca2+-dependent homeostasis of airway surface liquid volume in human cystic fibrosis airway epithelia.
    Coakley RD; Sun H; Clunes LA; Rasmussen JE; Stackhouse JR; Okada SF; Fricks I; Young SL; Tarran R
    J Clin Invest; 2008 Dec; 118(12):4025-35. PubMed ID: 19033671
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hyper-osmolarity and calcium chelation: Effects on cystic fibrosis mucus.
    Ermund A; Meiss LN; Gustafsson JK; Hansson GC
    Eur J Pharmacol; 2015 Oct; 764():109-117. PubMed ID: 26134505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.